Nektar Therapeutics announced the topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial.
The study focused on investigating rezpegaldesleukin, a novel immunology therapy, in patients with severe-to-very-severe alopecia areata.
Patients treated with rezpegaldesleukin showed significant improvements in hair regrowth and reduction in SALT scores, surpassing placebo results.
Primary Endpoint Achievement
Mean percentage reduction in SALT scores at 36 weeks achieved statistical significance for both rezpegaldesleukin treatment arms, demonstrating substantial efficacy in alopecia areata.
Safety Profile
The safety profile of rezpegaldesleukin was well-tolerated and consistent with previous reports, indicating its potential as a safe treatment option for alopecia areata.
Phase 3 Development Support
Positive Phase 2b results support the advancement of rezpegaldesleukin to Phase 3 development, promising progress in addressing alopecia areata.
- The study results establish the groundwork for further development of rezpegaldesleukin as a promising treatment for alopecia areata.
- Physicians and experts highlight the significant clinical efficacy of rezpegaldesleukin in providing meaningful hair regrowth, filling a critical gap in treatment options for this immune disorder.
The Phase 2b study results present compelling evidence of the efficacy and safety of rezpegaldesleukin in treating alopecia areata, signaling a potential breakthrough in the management of this challenging condition.